Search details
1.
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.
N Engl J Med
; 376(6): 536-547, 2017 02 09.
Article
in English
| MEDLINE | ID: mdl-28177873
2.
PPM1D-truncating mutations confer resistance to chemotherapy and sensitivity to PPM1D inhibition in hematopoietic cells.
Blood
; 132(11): 1095-1105, 2018 09 13.
Article
in English
| MEDLINE | ID: mdl-29954749
3.
The relative utilities of genome-wide, gene panel, and individual gene sequencing in clinical practice.
Blood
; 130(4): 433-439, 2017 07 27.
Article
in English
| MEDLINE | ID: mdl-28600338
4.
The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia.
Blood
; 129(4): 497-508, 2017 01 26.
Article
in English
| MEDLINE | ID: mdl-27756750
5.
SETD2 alterations impair DNA damage recognition and lead to resistance to chemotherapy in leukemia.
Blood
; 130(24): 2631-2641, 2017 12 14.
Article
in English
| MEDLINE | ID: mdl-29018079
6.
Age-related clonal hematopoiesis associated with adverse outcomes.
N Engl J Med
; 371(26): 2488-98, 2014 Dec 25.
Article
in English
| MEDLINE | ID: mdl-25426837
7.
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
Blood
; 125(9): 1367-76, 2015 Feb 26.
Article
in English
| MEDLINE | ID: mdl-25550361
8.
Whole exome sequencing of a breast tumor in a patient with Diamond Blackfan anemia.
Blood Cells Mol Dis
; 89: 102566, 2021 07.
Article
in English
| MEDLINE | ID: mdl-33862369
9.
CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia.
Nature
; 459(7249): 1000-4, 2009 Jun 18.
Article
in English
| MEDLINE | ID: mdl-19536265
10.
Discovery and Clinical Proof-of-Concept of RLY-2608, a First-in-Class Mutant-Selective Allosteric PI3Kα Inhibitor That Decouples Antitumor Activity from Hyperinsulinemia.
Cancer Discov
; 14(2): 240-257, 2024 Feb 08.
Article
in English
| MEDLINE | ID: mdl-37916956
11.
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF©) and determination of a threshold score for moderate symptoms.
Orphanet J Rare Dis
; 18(1): 69, 2023 03 25.
Article
in English
| MEDLINE | ID: mdl-36964624
12.
Integration of Genomic Sequencing Drives Therapeutic Targeting of PDGFRA in T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma.
Clin Cancer Res
; 29(22): 4613-4626, 2023 11 14.
Article
in English
| MEDLINE | ID: mdl-37725576
13.
Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
NEJM Evid
; 2(6): EVIDoa2200339, 2023 Jun.
Article
in English
| MEDLINE | ID: mdl-38320129
14.
Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF) in a phase 2 clinical study.
Orphanet J Rare Dis
; 16(1): 434, 2021 10 18.
Article
in English
| MEDLINE | ID: mdl-34663404
15.
Development of symptom-focused outcome measures for advanced and indolent systemic mastocytosis: the AdvSM-SAF and ISM-SAF©.
Orphanet J Rare Dis
; 16(1): 414, 2021 10 09.
Article
in English
| MEDLINE | ID: mdl-34627355
16.
Psychometric evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF).
Leuk Res
; 108: 106606, 2021 09.
Article
in English
| MEDLINE | ID: mdl-34004551
17.
Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial.
Nat Med
; 27(12): 2183-2191, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34873347
18.
Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial.
Nat Med
; 27(12): 2192-2199, 2021 12.
Article
in English
| MEDLINE | ID: mdl-34873345
19.
Deletion of ribosomal protein genes is a common vulnerability in human cancer, especially in concert with TP53 mutations.
EMBO Mol Med
; 9(4): 498-507, 2017 04.
Article
in English
| MEDLINE | ID: mdl-28264936
20.
Clonal Hematopoiesis Associated With Adverse Outcomes After Autologous Stem-Cell Transplantation for Lymphoma.
J Clin Oncol
; 35(14): 1598-1605, 2017 May 10.
Article
in English
| MEDLINE | ID: mdl-28068180